These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21789752)

  • 1. [Hypertricglyceridemia: prognostic impact and treatment options].
    Custodis F; Laufs U
    Dtsch Med Wochenschr; 2011 Jul; 136(30):1533-42. PubMed ID: 21789752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Increased triglycerides and/or low HDL cholesterol. A risk factor needing treatment?].
    Steinmetz A
    MMW Fortschr Med; 2002 Aug; 144(31-32):20-3. PubMed ID: 12422724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
    Malloy MJ; Kane JP
    Adv Intern Med; 2001; 47():111-36. PubMed ID: 11795072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol.
    Katcher HI; Hill AM; Lanford JL; Yoo JS; Kris-Etherton PM
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):45-78. PubMed ID: 19217512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.
    Stone NJ; Bilek S; Rosenbaum S
    Am J Cardiol; 2005 Aug; 96(4A):53E-59E. PubMed ID: 16098845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hypertriglyceridemia.
    Oh RC; Lanier JB
    Am Fam Physician; 2007 May; 75(9):1365-71. PubMed ID: 17508532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bridging the gap in treatment options for patients with hypertriglyceridemia.
    Underberg JA; Hays R
    J Fam Pract; 2007 Dec; 56(12 Suppl New):S24-31. PubMed ID: 18664339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M
    Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A physician's guide for the management of hypertriglyceridemia: the etiology of hypertriglyceridemia determines treatment strategy.
    Klop B; Wouter Jukema J; Rabelink TJ; Castro Cabezas M
    Panminerva Med; 2012 Jun; 54(2):91-103. PubMed ID: 22525564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing Hypertriglyceridemia in Daily Practice.
    Pramono LA; Harbuwono DS
    Acta Med Indones; 2015 Jul; 47(3):265-71. PubMed ID: 26586394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity and dyslipidemia.
    Repas T
    S D Med; 2011 Jul; 64(7):241-3, 245, 247 passim. PubMed ID: 21848021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.